

# Mundipharma's charter on the responsible medical use of opioid analgesics in pain management

## Mundipharma's charter on the responsible medical use of opioid analgesics in pain management

Opioid analgesics can be an important option for healthcare professionals to appropriately treat patients with moderate to severe pain. Notwithstanding this medical need, Mundipharma recognises that the use of prescription opioid medications is associated with risks of abuse, addiction and diversion. As a company that provides opioid medicines for appropriate and responsible medical and scientific use, we are committed to mitigating these risks and to supporting healthcare professionals in treating their patients in pain safely and responsibly.

The decision to prescribe opioid analgesics must carefully consider the patient's individual circumstances and balance the legitimate need for adequate pain relief with the risks of potential abuse, addiction and diversion. Regular and careful monitoring by the clinician is essential to ensure that continued use of these medicines meets an ongoing medical need, for which there are no suitable non-opioid treatments, to ensure the appropriate dose is applied, and duration of treatment is minimised.

Mundipharma is committed to reducing the risk of abuse, addiction and diversion through a secure supply chain, appropriate medical education for healthcare professionals, and responsible sales and marketing practices.

As part of this commitment, Mundipharma and its associated independent companies:

1. Strictly follow national and international laws, regulations and guidelines governing the appropriate development, manufacture, promotion and distribution of opioid medicines. Our Product Stewardship Committee provides an ethical framework in line with these laws, regulations, and guidelines. To the extent relevant national and international pain management guidelines indicate a more restricted usage than the applicable marketing authorisation, we follow the more restrictive guidelines in all cases.
2. Do not support the off-label use of opioid analgesics.
3. Support the education of healthcare professionals so they may independently assess the risk of abuse, addiction and diversion, by providing accurate, balanced and scientifically valid information about opioid analgesics along with other treatment options.
4. Choose not to promote or to provide proactive medical education about strong opioids for the treatment of chronic non-cancer pain, even though they remain indicated for this purpose. Medical information about the potential benefits and risks of strong opioids for chronic non-cancer pain is only provided in response to unsolicited requests from a healthcare professional.
5. Maintain strict global governance, which follows applicable laws and international codes, for all promotional and medical education activities and materials, including mandatory compliance and medical training of all employees who interact with healthcare professionals regarding opioid analgesics.
6. Assess the effectiveness of our controls through regular auditing and monitoring.
7. Promote our Integrity Line to enable anyone to report any issues or concerns without fear of retaliation and promptly investigate all reports and take appropriate actions.
8. Assess and audit our supply chains to reduce the risk of diversion or loss, and continually improve the security of the supply chain through effective reporting, monitoring, investigation, and corrective and preventative action planning.

**Mundipharma is committed to the highest ethical and legal standards. In the event you have any concerns or questions please direct them to:**

**Brian Sheehan**

Chief Scientific Officer

[brian.sheehan@mundipharma.com](mailto:brian.sheehan@mundipharma.com)

Or you can contact us at the [Mundipharma Integrity Line](#)

If you are a journalist, please contact:

**Lesley Ferguson White**

Senior Vice President, Communications

[lesley.ferguson-white@mundipharma.com](mailto:lesley.ferguson-white@mundipharma.com)